Vibalogics has initiated Phase I of its planned $150m investment in a late-phase clinical and commercial virotherapy manufacturing facility near Boston, Massachusetts.
The three-year investment plan includes the build out of a 110,000 sq. ft facility across redevelopment, equipment and personnel.
The CDMO which specializes in the production of oncolytic viruses, viral vector vaccines and viral vector gene therapy products, expects the site to be operational by the second half of 2021.
Vibalogics’ Chief Executive Officer Tom Hochuli is leading the CDMO’s U.S. expansion and global growth strategy.
“We are very excited about our choice of facility, as it meets both our current and future needs, giving us the ability to expand further to meet growing customer demand,” Hochuli said. “The site will provide a complete suite of virotherapy services to support drug developers and their most revolutionary products. The addition of a late stage clinical and commercial facility means we can easily tech transfer our customers’ products from our early phase manufacturing facility in Germany to the U.S., resulting in a complete end-to-end service from pre-clinical to commercial supply.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“This is a major milestone in our planned U.S. expansion, and in the advancement of our clinical and commercial offering to drug developers across the globe,” Stefan Beyer, President and Managing Director of Vibalogics GmbH said. “The decision to expand stems from high demand for biomanufacturing services and development capacity in viral vector vaccines and oncolytic viruses and is an important step in integrating our future late phase and commercial operations into our business.”